The first reprogramming therapy is cleared for a human trial. 'Cleared to test' and 'shown to work' are different sentences.

Life Biosciences announced today that the FDA has cleared its investigational new drug application for ER-100, which the company describes as the first cellular rejuvenation therapy using epigenetic reprogramming to be allowed into human trials. The therapy switches on three of the four Yamanaka factors — the genes that, in 2006, were shown to turn an adult cell back toward a stem cell — in a controlled, partial way, with the aim of making old cells act younger without losing their identity. The first trial is in two eye diseases, open-angle glaucoma and a form of optic-nerve stroke with no approved treatment, and it is a Phase 1: a safety study, beginning this quarter. When we wrote about NewLimit's financing in October, we said the thing to watch was an IND filing and which disease it named. Here is one, and it names the eye.

What a Phase 1 can tell you. Whether the therapy is tolerated, what the immune system does, what dose to try next, and — in this case — some early visual measurements. It cannot tell you whether the treatment works, and it is not designed to; efficacy comes later, in larger trials, if the safety data permit them. Everything known about ER-100's benefit comes from animal models, where the company reports safety and efficacy. On the evidence hierarchy that is where it sits: an animal result with permission to become a human one. The "first" claim is the company's, and we repeat it as theirs. The eye is a sensible place to start — a contained organ, measurable function, serious unmet need — and it is a long way from aging.

Loree’s take

I tell patients that a Phase 1 trial is a question, not an answer, and the question is "is this safe enough to keep studying?" The gap between today and anything a clinician could prescribe is years, several trials and a high failure rate at each step. I am glad the work is in people. I would be gladder if the products already sold with "reprogramming" and "cellular rejuvenation" on the label had waited for this day before borrowing the words.

Ben’s take

This is what credible longevity biotech looks like, and it is slow, specific and unglamorous: one therapy, one disease, one safety trial, a decade of risk ahead. It is also the standard against which to measure every consumer product using the same vocabulary. The company cleared to test in humans today will not sell you anything this year. The companies selling you cellular rejuvenation this year have cleared nothing.

What to watch. Not headlines about aging. Watch for the trial's safety results and whether a Phase 2 follows, and in which disease. If reprogramming becomes a medicine, it will do so one organ at a time, for patients who are sick, after trials — and the first of those trials started this quarter, in the eye.